Skip to main navigation
Oric Logo Oric Logo OricPharma logo
  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Founders
    • Contact
  • Pipeline
    • Overview
    • Rinzimetostat (ORIC-944)
    • Enozertinib (ORIC-114)
    • Publications
  • Patients
    • Overview
    • Clinical Trials
  • Investors & News
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Quarterly Results
    • Investor FAQs
    • Contact IR
  • Careers
    • Overview
    • Culture & Values
    • Benefits
    • Current Openings
CONTACT US
info@oricpharma.com
(650) 388-5600
 
Scientist in lab

Quarterly Results

Quarterly Results

Show all

2023

Q2
  • Earnings Release
  • Form 10-Q
Q1
  • Earnings Release
  • Form 10-Q

2022

Q4
  • Earnings Release
  • Form 10-K
Q3
  • Earnings Release
  • Form 10-Q
Q2
  • Earnings Release
  • Form 10-Q
Q1
  • Earnings Release
  • Form 10-Q

2021

Q4
  • Earnings Release
  • Form 10-K
Q3
  • Earnings Release
  • Form 10-Q
Q2
  • Earnings Release
  • Form 10-Q
Q1
  • Earnings Release
  • Form 10-Q

2020

Q4
  • Earnings Release
  • Form 10-K
Print PRINT
Email Page EMAIL PAGE
Contact IR Contact IR
RSS RSS
Email Alerts Email Alerts
Contact
info@oricpharma.com
(650) 388-5600
 
  • Home
  • Pipeline
  • Investors & News
  • Privacy Policy
  • About
  • Patients
  • Careers
  • Terms of Use
©2026 ORIC Pharmaceuticals, Inc. All rights reserved.
ORIC and the stylized ORIC mark are registered trademarks of ORIC Pharmaceuticals, Inc.